Emergency management of bleeding associated with old and new oral anticoagulants

Clinical Cardiology

Volumn 35, Issue 12, 2012, Pages 730-737

  Frank Peacock, W ^a   Gearhart, Michelle M ^b   Mills, Roger M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Janssen Scientific Affairs   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FRESH FROZEN PLASMA; PROTEIN C; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; EMERGENCY TREATMENT; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOPLASTIN TIME;

EID: 84870924316     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22037     Document Type: Review

References (46)

1. Crowther MA, Warkentin TE., Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008; 111: 4871 -4879.
2. Vigué B., Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care. 2009; 13: 209.
3. Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008; 24: 87 -97.
4. Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006; 21: 73 -77.
5. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287: 337 -344.
6. Wysowski DK, Nourjah P, Swartz L., Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007; 167: 1414 -1419.
7. Nutescu E, Chuatrisorn I, Hellenbart E., Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011; 31: 326 -343.
8. Zikria J, Ansell J., Oral anticoagulation with Factor Xa and thrombin inhibitors: is there an alternative to warfarin? Discov Med. 2009; 8: 196 -203.
9. Kimmel SE., Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008; 9: 677 -686.
10. Prasad S, Wootten MR, Kulinski N, et al. What to do when warfarin therapy goes too far. J Fam Pract. 2009; 58: 346 -352.
11. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007; 82: 82 -92.
12. Wiedermann CJ, Stockner I., Warfarin-induced bleeding complications-clinical presentation and therapeutic options. Thromb Res. 2008; 122 (suppl 2): S13 -S18.
13. Pabinger I, Tiede A, Kalina U, et al. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol. 2010; 89: 309 -316.
14. Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals. 2011.
15. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J Med Chem. 2005; 48: 5900 -5908.
16. Johnson & Johnson Pharmaceutical Research & Development. Rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation. Advisory committee briefing document; 2011.
17. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765 -2775.
18. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372: 31 -39.
19. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776 -2786.
20. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373: 1673 -1680.
21. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883 -891.
22. dummy Pradaxa (dabigatran etexilate capsules) [package insert]. Ingelheim, Germany: Boehringer Ingelheim Pharma GmbH & Co. 2011. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
23. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116 -1127.
24. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003; 163: 2469 -2473.
25. Bershad EM, Suarez JI., Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010; 12: 403 -413.
26. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003; 1: 2368 -2373.
27. Hall AB, Carson BC., Reversal of warfarin-induced coagulopathy: review of treatment options. J Emerg Nurs. 2012; 38: 98 -101.
28. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004; 126: 139 -152.
29. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008; 83: 137 -143.
30. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006; 37: 151 -155.
31. Makris M, van Veen JJ, Maclean R., Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010; 29: 171 -181.
32. Logan AC, Yank V, Stafford RS., Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011; 154: 516 -522.
33. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011; 154: 529 -540.
34. Skolnick BE, Mathews DR, Khutoryansky NM, et al. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010; 116: 693 -701.
35. Scott LJ., Prothrombin complex concentrate (Beriplex P/N). Drugs. 2009; 69: 1977 -1984.
36. Monroe DM, Hoffman M., What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006; 26: 41 -48.
37. Morgenstern LB, Hemphill JC III, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41: 2108 -2129.
38. Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther. 2011; 53: 78 -79.
39. Anti-Inhibitor Coagulant Complex, nanofiltered and vapor-heated lyophilized powder for solution [package insert]. Deerfield, IL: Baxter Healthcare Corporation. 2011.
40. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124: 1573 -1579.
41. Mills RM, Berkowitz RD, Damaraju CV, et al. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study. Poster presented at: International Society for Thrombosis and Haemostasis (ISTH); July 23 -29, 2011; Kyoto, Japan.
42. Gruber A, Marzec UM, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood. 2008; 112: 3825.
43. Perzborn E, Harwardt M., Recombinant factor VIIA partially reverses the effects of the factor XA inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost. 2007; 5 (suppl 2): Abstract P-W-640.
44. Eerenberg ES, Sijpkens MK, Kamphuisen PW, et al. Prothrombin complex concentrate reverses the anticoagulant effect of rivaroxaban in healthy volunteers. Blood. 2010;116:Abstract 1094.
45. Guyatt GH, Norris SL, Schulman S, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 suppl): e89S -e119S.
46. Cairns JA, Connolly S, McMurtry S, et al. CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011; 27: 74 -90.